Justine Yang Bruce, MD

Justine Yang Bruce, MD, is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine at the University of Wisconsin, as well as the director of the VA Medical Oncology Clinical Research Program and dhair of the Protocol Review and Monitoring Committee at the University of Wisconsin Carbone Cancer Center

Articles by Justine Yang Bruce, MD

Justine Bruce, MD, faculty member, Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin; director, VA Medical Oncology Clinical Research Program, chair, Protocol Review and Monitoring Committee, University of Wisconsin Carbone Cancer Center

Toripalimab Plus De-Intensified Chemo Represents the Potential Future of Nasopharyngeal Cancer Management: With Justine Bruce, MD

ByJustine Yang Bruce, MD

July 10th 2025

Dr Bruce discusses treatment strategies for nasopharyngeal cancer, including how first-line toripalimab plus chemotherapy has shown improved OS.

Window of Opportunity Trials Are Needed for Novel Tissue Biomarker Analysis in Head and Neck Cancers

ByJustine Yang Bruce, MD,Deric L. Wheeler, PhD

October 19th 2023

Drug development is a difficult and ever-changing process, with new agents being developed by industry and academic partners.

Justine Yang Bruce, MD

Articles by Justine Yang Bruce, MD

Toripalimab Plus De-Intensified Chemo Represents the Potential Future of Nasopharyngeal Cancer Management: With Justine Bruce, MD

Window of Opportunity Trials Are Needed for Novel Tissue Biomarker Analysis in Head and Neck Cancers

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma